Vyome Holdings Inc Dossier - Source-backed chat

Vyome Holdings Inc

HINDNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.33

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $1.93Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $13.5M

Enterprise Value $4.7M

Shares Outstanding 7M diluted

Next Earnings Date13 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Vyome Holdings, Inc. (Nasdaq: HIND) is a clinical-stage biopharmaceutical company leveraging a hyper cost-efficient US-India innovation corridor to develop therapies for immuno-inflammatory and rare diseases. The investment thesis centers on its lead asset, VT-1953, a topical gel targeting Malignant Fungating Wounds (MFW). VT-1953 has demonstrated strong Phase 2 efficacy in reducing severe malodor and lesion pain, addressing a critical unmet need with no current FDA-approved therapies. Backed by a clean capital structure with zero debt, no preferred stock, and a growing cash balance of $8.8 million as of Q1 2026, Vyome is well-positioned to advance VT-1953 into pivotal Phase 3 trials. Strategic expansion, such as the recent in-licensing of selective JAK inhibitor assets from Impetis Biosciences, further broadens its addressable market under a capital-light model.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets2 analysts · as of 18 Aug 2026

Low · most bearish analyst$8.00

Mean target$11.50

High · most bullish analyst$15.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$8.0020%

The FDA requests additional preclinical toxicology or pharmacokinetic studies before allowing VT-1953 to enter Phase 3 trials, delaying clinical timelines. Prolonged development timelines increase the cash burn rate, forcing the company to execute dilutive equity raises. Clinical progress on the JAK inhibitor pipeline remains slow, keeping the stock range-bound near its historical lows.

Base CaseCentral scenario

$11.5050%

Matches the consensus mean

Vyome successfully secures FDA alignment on its Phase 3 development plan for VT-1953 and begins trial initiation. The company maintains its disciplined cash burn rate, utilizing its $8.8 million cash reserve and strategic capital raises to fund clinical milestones. The market begins to price in the high probability of success for VT-1953 as clinical trial sites open, driving steady valuation expansion toward consensus analyst targets.

Bull CaseUpside scenario

$15.0030%

The FDA grants Orphan Drug Designation and provides highly favorable guidance for a streamlined, single pivotal Phase 3 trial for VT-1953. Rapid enrollment and positive Phase 3 data validate VT-1953's multi-billion dollar potential in MFW, triggering a major licensing deal or acquisition. Concurrently, the in-licensed JAK inhibitor assets from Impetis Biosciences show rapid preclinical progress, unlocking access to the $57B global market.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong Phase 2 clinical data for lead asset VT-1953, showing statistically significant reductions in MFW-associated malodor (p=0.0020) and lesion pain (p=0.0020).
Clean capital structure with zero debt, no preferred stock, and no toxic financing instruments, supported by $8.8 million in cash as of March 31, 2026.
First-mover advantage in Malignant Fungating Wounds (MFW), a severe condition with no currently approved FDA therapies.
Strategic, capital-light expansion through the in-licensing of selective JAK inhibitor assets from Impetis Biosciences (a TATA Enterprise) without upfront or milestone payments.

Key Investment Risks

Clinical development risk inherent to early-stage biotech, with the potential for Phase 3 trial delays or failure to meet primary endpoints.
Regulatory risks, including potential FDA requests for additional safety, toxicology, or manufacturing data prior to pivotal trial initiation.
Limited current revenues ($31,591 in Q1 2026) and ongoing net losses ($985,521 in Q1 2026) make the company dependent on capital markets or partnerships for long-term funding.

Thesis Invalidation Triggers

FDA rejection of the Orphan Drug Designation application or clinical hold placed on the VT-1953 program.
Failure to align with the FDA on a viable Phase 3 clinical trial design, resulting in prohibitive development costs or timelines.
Severe cash depletion below $2.0 million without securing non-dilutive funding, strategic partnerships, or additional capital.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.